Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 2,402 Shares

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 2,402 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $98,265.82. Following the transaction, the chief executive officer now owns 662,692 shares in the company, valued at $27,110,729.72. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $36.71 on Tuesday. The stock has a fifty day moving average of $46.54 and a 200 day moving average of $45.47. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of -10.86 and a beta of 2.15. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same quarter last year, the firm posted ($0.75) earnings per share. The firm’s revenue was up 24.1% on a year-over-year basis. As a group, research analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analyst Ratings Changes

TWST has been the subject of a number of analyst reports. Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. TD Cowen reissued a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. JPMorgan Chase & Co. increased their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday, February 4th. Barclays set a $58.00 price objective on Twist Bioscience and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, Wolfe Research initiated coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and an average target price of $54.40.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA lifted its position in Twist Bioscience by 215.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock valued at $1,324,000 after buying an additional 20,035 shares during the period. Barclays PLC lifted its position in Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after buying an additional 104,420 shares during the period. FMR LLC lifted its position in Twist Bioscience by 6.0% during the third quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after buying an additional 12,327 shares during the period. Avanza Fonder AB purchased a new position in Twist Bioscience during the fourth quarter valued at $1,059,000. Finally, BNP Paribas Financial Markets lifted its position in Twist Bioscience by 128.1% during the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after buying an additional 21,357 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.